Phase 1 Schizophrenia trials recruiting now

All Schizophrenia trials, every phase

Other phases for Schizophrenia

Phase 1 Schizophrenia trials

• A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
  NCT07423546 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
  NCT07230652 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
  NCT07734493 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 10 locations
• A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
  NCT07615426 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 8 locations
• A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
  NCT07061288 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 8 locations
• Acetazolamide for Treatment Resistant Schizophrenia
  NCT04887792 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
  NCT04789915 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 1 location
• Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
  NCT03794076 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
  NCT05025605 · Phase: Phase 1 · Ages: 10 Years to 17 Years · Sex: All (male and female) · 5 locations
• Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia
  NCT07484204 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 4 locations
• Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
  NCT06504290 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 4 locations
• Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans
  NCT06058702 · Phase: Phase 1 · Ages: 21 Years to 60 Years · Sex: All (male and female) · 1 location
• Imaging Synapses With [11C] UCB-J in the Human Brain
  NCT04038840 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Ocrelizumab for Psychosis by Autoimmunity
  NCT03971487 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 35 Years · Sex: All (male and female) · 1 location
• Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
  NCT07185815 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 6 locations
• The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.
  NCT06674694 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Tolerability of MDMA in Schizophrenia
  NCT05770375 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.